BCYC
Bicycle Therapeutics Ltd
3.70$
-1.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2,832.7% | 31.3% | 8.5% | 17.5% | 1,705.8% | 1,512.2% | 574.0% | 2,432.5% | – | 73.1% | – | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | -1,605.8% | -1,412.2% | -474.0% | -2,332.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 744.9% | 838.4% | 178.5% | 427.9% | 1,803.6% | 1,342.4% | 591.9% | 2,432.5% | 497.9% | 108.0% | 5,513.1% | 6,543.7% | 327.2% | |
| 290.9% | 282.3% | 84.2% | 171.5% | 682.2% | 566.9% | 211.7% | 658.8% | 162.1% | 43.5% | 1,981.4% | 2,230.2% | 116.8% | |
| 1,049.1% | 1,117.4% | 262.4% | 598.3% | 780.0% | 412.6% | 229.6% | 633.3% | 658.6% | 151.4% | 7,494.5% | 8,773.9% | 443.7% | |
| -949.1% | -1,017.4% | -162.4% | -498.3% | -2,385.9% | -1,824.8% | -703.7% | -2,965.8% | -558.6% | -51.4% | -7,394.5% | -8,673.9% | -343.7% | |
| 15.2% | 15.4% | 4.2% | 8.8% | 1.2% | 1.4% | 0.5% | 1.8% | 0.4% | 0.1% | 5.4% | 7.0% | 0.3% | |
| -889.9% | -915.0% | -137.8% | -424.1% | -2,027.3% | -1,428.0% | -619.8% | -2,711.7% | -501.9% | -39.4% | -6,838.0% | -7,987.8% | -308.3% | |
| 42.5% | 6.0% | -1.8% | 1.2% | -128.8% | -29.2% | -10.9% | -7.9% | 1.7% | 2.6% | 19.4% | 14.3% | 2.8% | |
| -932.3% | -921.0% | -136.0% | -425.3% | -1,898.4% | -1,398.4% | -608.9% | -2,703.8% | -503.7% | -42.0% | -6,857.4% | -8,002.1% | -311.1% | |
| -843.1% | -868.6% | -125.1% | -397.7% | -2,287.3% | -1,380.7% | -603.9% | -2,651.8% | -486.6% | -36.5% | -6,705.3% | -7,811.1% | -299.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.